The global intravenous (IV) hydration therapy market size accounted for USD 2.93 billion in 2025 and is predicted to be worth around USD 5.84 billion by 2034, registering a CAGR of 7.98% between 2025 and 2034. The North America intravenous (IV) hydration therapy market size was evaluated at USD 1.27 billion in 2024 and is expected to grow at a CAGR of 7.99% during the forecast year. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Intravenous (IV) Hydration Therapy Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Intravenous (IV) Hydration Therapy Market, by Service
8.1.1 Immune Boosters
8.1.1.1. Market Revenue and Forecast
8.1.2. Energy Boosters
8.1.2.1. Market Revenue and Forecast
8.1.3. Skin Care
8.1.3.1. Market Revenue and Forecast
8.1.4. Migraine
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
9.1. Intravenous (IV) Hydration Therapy Market, by Component
9.1.1. Medicated
9.1.1.1. Market Revenue and Forecast
9.1.2. Non-Medicated
9.1.2.1. Market Revenue and Forecast
10.1. Intravenous (IV) Hydration Therapy Market, by End-Use
10.1.1. Hospitals and Clinics
10.1.1.1. Market Revenue and Forecast
10.1.2. Wellness Centers and Spas
10.1.2.1. Market Revenue and Forecast
10.1.3. Home Healthcare
10.1.3.1. Market Revenue and Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Service
11.1.2. Market Revenue and Forecast, by Component
11.1.3. Market Revenue and Forecast, by End-Use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service
11.1.4.2. Market Revenue and Forecast, by Component
11.1.4.3. Market Revenue and Forecast, by End-Use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service
11.1.5.2. Market Revenue and Forecast, by Component
11.1.5.3. Market Revenue and Forecast, by End-Use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service
11.2.2. Market Revenue and Forecast, by Component
11.2.3. Market Revenue and Forecast, by End-Use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service
11.2.4.2. Market Revenue and Forecast, by Component
11.2.4.3. Market Revenue and Forecast, by End-Use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service
11.2.5.2. Market Revenue and Forecast, by Component
11.2.5.3. Market Revenue and Forecast, by End-Use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service
11.2.6.2. Market Revenue and Forecast, by Component
11.2.6.3. Market Revenue and Forecast, by End-Use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service
11.2.7.2. Market Revenue and Forecast, by Component
11.2.7.3. Market Revenue and Forecast, by End-Use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service
11.3.2. Market Revenue and Forecast, by Component
11.3.3. Market Revenue and Forecast, by End-Use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service
11.3.4.2. Market Revenue and Forecast, by Component
11.3.4.3. Market Revenue and Forecast, by End-Use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service
11.3.5.2. Market Revenue and Forecast, by Component
11.3.5.3. Market Revenue and Forecast, by End-Use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service
11.3.6.2. Market Revenue and Forecast, by Component
11.3.6.3. Market Revenue and Forecast, by End-Use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service
11.3.7.2. Market Revenue and Forecast, by Component
11.3.7.3. Market Revenue and Forecast, by End-Use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service
11.4.2. Market Revenue and Forecast, by Component
11.4.3. Market Revenue and Forecast, by End-Use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service
11.4.4.2. Market Revenue and Forecast, by Component
11.4.4.3. Market Revenue and Forecast, by End-Use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service
11.4.5.2. Market Revenue and Forecast, by Component
11.4.5.3. Market Revenue and Forecast, by End-Use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service
11.4.6.2. Market Revenue and Forecast, by Component
11.4.6.3. Market Revenue and Forecast, by End-Use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service
11.4.7.2. Market Revenue and Forecast, by Component
11.4.7.3. Market Revenue and Forecast, by End-Use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service
11.5.2. Market Revenue and Forecast, by Component
11.5.3. Market Revenue and Forecast, by End-Use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service
11.5.4.2. Market Revenue and Forecast, by Component
11.5.4.3. Market Revenue and Forecast, by End-Use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service
11.5.5.2. Market Revenue and Forecast, by Component
11.5.5.3. Market Revenue and Forecast, by End-Use
12.1. Core IV Therapy, LLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Otsuka Pharmaceutical Co., Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Baxter International Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Drip Hydration
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. NexGen Health
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. JW Life Science Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Amanta Healthcare
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Cryojuvenate UK Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. B. Braun Medical Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description